Neurological Disorders

The human body has an Endocannabinoid System (ECS), not a Benzodiazepine System. The receptors of the ECS system (namely CB1) play pivotal roles in anxiolytic action of benzodiazepines. In other words, benzodiazepine drugs (such as Alprazolam -“Xanax”; Chlordiazepoxide -“Librium”; Clobazepam – “Onfi”; Clonazepam -“Klonopin”; and many others) have an anxiolytic mechanism of action that utilize the ECS receptor CB1.   The ECS is emerging as primary drug targets for treating numerous neurological disorders including: Parkinson’s disease; Alzheimer’s disease; multiple sclerosis; neuropathic pain; schizophrenia; anxiety; depression; addiction; post-concussion syndrome, and post-traumatic stress disorders. Many peer reviewed research papers are using phytocannabinoids such as CBD to confirm the widely held assertion that natural plant medicine is as effective as pharmaceutical drugs for addressing nurological discorders.

What are the Scientists Saying about ECS and Neuro?


What are the Scientists Saying about ECS and Epilepsy?


What are the Scientists Saying about ECS and Dementia?


What are the Scientists Saying about ECS and Parkinson’s Disease?


What are the Scientists Saying about ECS and Cannabinoids?


What are the Scientists Saying about ECS and GABAergic Transmission?